Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression

Vito Alessandro Lasorsa, Daniela Formicola, Piero Pignataro, Flora Cimmino, Francesco Maria Calabrese, Jaume Mora, Maria Rosaria Esposito, Marcella Pantile, Carlo Zanon, Marilena De Mariano, Luca Longo, Michael D. Hogarty, Carmen De Torres, Gian Paolo Tonini, Achille Iolascon, Mario Capasso

Research output: Contribution to journalArticlepeer-review

Abstract

The spectrum of somatic mutation of the most aggressive forms of neuroblastoma is not completely determined. We sought to identify potential cancer drivers in clinically aggressive neuroblastoma. Whole exome sequencing was conducted on 17 germline and tumor DNA samples from high-risk patients with adverse events within 36 months from diagnosis (HREvent3) to identify somatic mutations and deep targeted sequencing of 134 genes selected from the initial screening in additional 48 germline and tumor pairs (62.5% HR-Event3 and high-risk patients), 17 HR-Event3 tumors and 17 human-derived neuroblastoma cell lines. We revealed 22 significantly mutated genes, many of which implicated in cancer progression. Fifteen genes (68.2%) were highly expressed in neuroblastoma supporting their involvement in the disease. CHD9, a cancer driver gene, was the most significantly altered (4.0% of cases) after ALK. Other genes (PTK2, NAV3, NAV1, FZD1 and ATRX), expressed in neuroblastoma and involved in cell invasion and migration were mutated at frequency ranged from 4% to 2%. Focal adhesion and regulation of actin cytoskeleton pathways, were frequently disrupted (14.1% of cases) thus suggesting potential novel therapeutic strategies to prevent disease progression. Notably BARD1, CHEK2 and AXIN2 were enriched in rare, potentially pathogenic, germline variants. In summary, whole exome and deep targeted sequencing identified novel cancer genes of clinically aggressive neuroblastoma. Our analyses show pathway-level implications of infrequently mutated genes in leading neuroblastoma progression.

Original languageEnglish
Pages (from-to)21840-21852
Number of pages13
JournalOncotarget
Volume7
Issue number16
DOIs
Publication statusPublished - Apr 19 2016

Keywords

  • Cancer driver genes
  • High risk
  • Neuroblastoma
  • NGS
  • Somatic mutation

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression'. Together they form a unique fingerprint.

Cite this